-
市场
-
产品
-
资讯
-
Moo社区
-
课堂
-
查看更多
-
功能介绍
-
费用费用透明,无最低余额限制
投资选择、功能介绍、费用相关信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 浅色
This Insider Has Just Sold Shares In New Ray Medicine International Holding Limited (HKG:6108)
This Insider Has Just Sold Shares In New Ray Medicine International Holding Limited (HKG:6108)
Some New Ray Medicine International Holding Limited (HKG:6108) shareholders may be a little concerned to see that insider Wen Xiaodong recently sold a substantial HK$199m worth of stock at a price of HK$0.61 per share. Probably the most concerning element of the whole transaction is that the disposal amounted to 85% of their entire holding.
View our latest analysis for New Ray Medicine International Holding
New Ray Medicine International Holding Insider Transactions Over The Last Year
Notably, that recent sale by Wen Xiaodong is the biggest insider sale of New Ray Medicine International Holding shares that we've seen in the last year. While we don't usually like to see insider selling, it's more concerning if the sales take place at a lower price. The good news is that this large sale was at well above current price of HK$0.31. So it may not shed much light on insider confidence at current levels.
Wen Xiaodong bought a total of 597.74m shares over the year at an average price of HK$0.70. You can see a visual depiction of insider transactions (by companies and individuals) over the last 12 months, below. If you want to know exactly who sold, for how much, and when, simply click on the graph below!
SEHK:6108 Insider Trading Volume May 16th 2022New Ray Medicine International Holding is not the only stock that insiders are buying. For those who like to find winning investments this free list of growing companies with recent insider purchasing, could be just the ticket.
Does New Ray Medicine International Holding Boast High Insider Ownership?
Looking at the total insider shareholdings in a company can help to inform your view of whether they are well aligned with common shareholders. A high insider ownership often makes company leadership more mindful of shareholder interests. New Ray Medicine International Holding insiders own 75% of the company, currently worth about HK$389m based on the recent share price. Most shareholders would be happy to see this sort of insider ownership, since it suggests that management incentives are well aligned with other shareholders.
What Might The Insider Transactions At New Ray Medicine International Holding Tell Us?
It is good to see the recent insider purchase. And an analysis of the transactions over the last year also gives us confidence. However, we note that the company didn't make a profit over the last twelve months, which makes us cautious. Along with the high insider ownership, this analysis suggests that insiders are quite bullish about New Ray Medicine International Holding. That's what I like to see! So while it's helpful to know what insiders are doing in terms of buying or selling, it's also helpful to know the risks that a particular company is facing. To assist with this, we've discovered 2 warning signs that you should run your eye over to get a better picture of New Ray Medicine International Holding.
Of course, you might find a fantastic investment by looking elsewhere. So take a peek at this free list of interesting companies.
For the purposes of this article, insiders are those individuals who report their transactions to the relevant regulatory body. We currently account for open market transactions and private dispositions, but not derivative transactions.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Some New Ray Medicine International Holding Limited (HKG:6108) shareholders may be a little concerned to see that insider Wen Xiaodong recently sold a substantial HK$199m worth of stock at a price of HK$0.61 per share. Probably the most concerning element of the whole transaction is that the disposal amounted to 85% of their entire holding.
一些新光医药国际控股有限公司(HKG:6108)股东们看到内部人士温晓东最近以每股0.61港元的价格出售了价值1.99亿港元的大量股票,可能会有点担心。可能整个交易中最令人担忧的因素是,出售的股份占其全部持股的85%。
View our latest analysis for New Ray Medicine International Holding
查看我们对新光医药国际控股的最新分析
New Ray Medicine International Holding Insider Transactions Over The Last Year
新光医药国际控股公司去年的内幕交易
Notably, that recent sale by Wen Xiaodong is the biggest insider sale of New Ray Medicine International Holding shares that we've seen in the last year. While we don't usually like to see insider selling, it's more concerning if the sales take place at a lower price. The good news is that this large sale was at well above current price of HK$0.31. So it may not shed much light on insider confidence at current levels.
值得注意的是,温晓东最近出售的股票是我们去年看到的最大规模的新光医药国际控股股份内幕交易。虽然我们通常不喜欢看到内幕出售,但如果以更低的价格出售,人们更担心的是。好消息是,这笔大笔交易的价格远高于目前0.31港元的价格。因此,在目前的水平上,这可能不会让人对内部人士的信心有太多了解。
Wen Xiaodong bought a total of 597.74m shares over the year at an average price of HK$0.70. You can see a visual depiction of insider transactions (by companies and individuals) over the last 12 months, below. If you want to know exactly who sold, for how much, and when, simply click on the graph below!
温晓东全年共买入5.9774亿股,均价为0.70港元。你可以在下面看到过去12个月(由公司和个人)进行的内幕交易的直观描述。如果你想知道到底是谁卖了,卖了多少钱,什么时候卖的,只需点击下面的图表!
New Ray Medicine International Holding is not the only stock that insiders are buying. For those who like to find winning investments this free list of growing companies with recent insider purchasing, could be just the ticket.
新光医药国际控股并不是内部人士买入的唯一股票。对于那些想要找到赢得投资这免费最近有内幕收购的不断增长的公司名单可能就是合适的选择。
Does New Ray Medicine International Holding Boast High Insider Ownership?
新光医药国际控股公司是否拥有高度的内部人持股?
Looking at the total insider shareholdings in a company can help to inform your view of whether they are well aligned with common shareholders. A high insider ownership often makes company leadership more mindful of shareholder interests. New Ray Medicine International Holding insiders own 75% of the company, currently worth about HK$389m based on the recent share price. Most shareholders would be happy to see this sort of insider ownership, since it suggests that management incentives are well aligned with other shareholders.
看看一家公司的内部人持股总数,可以帮助你了解他们是否与普通股股东很好地结合在一起。内部人持股比例较高往往会让公司领导层更加关注股东利益。新光医药国际控股有限公司内部人士持有该公司75%的股份,按近期股价计算,目前价值约3.89亿港元。大多数股东将乐于看到这种内部人持股,因为这表明管理层的激励与其他股东很好地结合在一起。
What Might The Insider Transactions At New Ray Medicine International Holding Tell Us?
新光医药国际控股有限公司的内幕交易可能告诉我们什么?
It is good to see the recent insider purchase. And an analysis of the transactions over the last year also gives us confidence. However, we note that the company didn't make a profit over the last twelve months, which makes us cautious. Along with the high insider ownership, this analysis suggests that insiders are quite bullish about New Ray Medicine International Holding. That's what I like to see! So while it's helpful to know what insiders are doing in terms of buying or selling, it's also helpful to know the risks that a particular company is facing. To assist with this, we've discovered 2 warning signs that you should run your eye over to get a better picture of New Ray Medicine International Holding.
很高兴看到最近的内幕收购。对过去一年交易的分析也给了我们信心。然而,我们注意到该公司在过去12个月里没有盈利,这让我们保持谨慎。除了高内部人持股,这一分析表明,内部人相当看好新光医药国际控股公司。这就是我想看到的!因此,虽然了解内部人士在买入或卖出方面做了什么是有帮助的,但了解一家特定公司面临的风险也是有帮助的。为了帮助这一点,我们发现2个警告标志你应该扫视一下,才能更好地了解新光医药国际控股公司。
Of course, you might find a fantastic investment by looking elsewhere. So take a peek at this free list of interesting companies.
当然了,如果你把目光投向别处,你可能会发现这是一笔很棒的投资。所以让我们来看看这个免费有趣的公司名单。
For the purposes of this article, insiders are those individuals who report their transactions to the relevant regulatory body. We currently account for open market transactions and private dispositions, but not derivative transactions.
就本文而言,内部人是指向相关监管机构报告其交易的个人。我们目前负责公开市场交易和私人处置,但不包括衍生品交易。
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
对这篇文章有什么反馈吗?担心内容吗? 保持联系直接与我们联系。或者,也可以给编辑组发电子邮件,地址是implywallst.com。
本文由Simply Wall St.撰写,具有概括性。我们仅使用不偏不倚的方法提供基于历史数据和分析师预测的评论,我们的文章并不打算作为财务建议。它不构成买卖任何股票的建议,也没有考虑你的目标或你的财务状况。我们的目标是为您带来由基本面数据驱动的长期重点分析。请注意,我们的分析可能不会将最新的对价格敏感的公司公告或定性材料考虑在内。Simply Wall St.对上述任何一只股票都没有持仓。
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
风险及免责提示
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用浏览器的分享功能,分享给你的好友吧